This is an aggregated industry headline. Read the full story at FierceBiotech →
At first public hearing for FDA's CNPV program, industry support meets 'deep concern' from experts
On Thursday, the public had the first chance to air their grievances about the FDA's controversial Commissioner's National Priority Voucher (CNPV) pilot program, the flagship initiative of recently departed agency leader Marty Makary, M.D.
By FierceBiotech
· Jun 5, 2026
· via FierceBiotech
Image: FierceBiotech
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
With a resounding unanimous vote, the U.S. Supreme Court has sided with Hikma Pharmaceuticals, ruling that its…
The WeekBriefing
The Trump administration plans to strip job protections from around 8,000 NIH officials overseeing research gr…
The WeekDrug Channels ↗
Today's guest post comes from Stephen Hom, Co-Founder, EVP & Chief Operating Officer of RIS Rx. Drawing on RIS…